Experimental Drug Development Centre (EDDC)

Happy Deepavali! From all of us here at EDDC, we wish everyone a joyful and peaceful holiday filled with warmth and happiness. 🪔✨ #EDDCsg #ESG #Deepavali2024 #Diwali2024

Following our recent ESMO poster presentation of Phase 1 dose escalation data for the EBC-129-01 trial (NCT05701527), we are happy to announce that we have completed enrolment of the pancreatic ductal adenocarcinoma (#PDAC) cohort in the ongoing dose expansion! Enrolment in cohorts with #GastroesophagealAdenocarcinoma and cohorts with other IHC positive #SolidTumours is ongoing. Find out more details about the trial below! A Study of EBC-129 in Advanced Solid Tumours: https://lnkd.in/gquecHwU A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours: https://lnkd.in/gXu5xaFD #EDDCsg #ESMO2024 #Oncology #GastricCancer #GEJCancer #GOJCancer #EsophagealCancer #OesophagealCancer #LungCancer #PancreaticCancer #EDDCsg #OncologyResearch #CancerResearch #CancerTrial #PatientRecruitment Veronica Diermayr PhD Julienne Cometa Venkateshan SP Hsin-Ee Chia Kunal Shah, PMP®

Wonder what AI has contributed towards small molecule drug discovery so far? In this Editorial from the Journal of Medicinal Chemistry, Dr Weijun Xu summarises the recent developments in Computer-Aided Drug Design (CADD) and Artificial Intelligence Drug Discovery (AIDD), outlining the successes, challenges and the opportunities that come along with these advancements for small molecule drug discovery. Read the full publication here: https://lnkd.in/gih4CGdF #EDDCsg #DrugDiscovery #ComputationalSciences #SmallMolecule #Publication

We are thrilled to announce our participation in ASK Health Asia's 2024 APAC Health and Life Sciences Summit! Our Deputy CEO, Dr Hwee Ching Ang, will be joining an esteemed panel on 11 November from 11:25am to 12:15pm, titled "Leaders' Insights: How Might We Create a Conducive Environment for Innovation and Successful Commercialisation in APAC." We're excited to share insights and explore how we can foster innovation and drive successful commercialisation across the region. Do join us in this important conversation as we work together to advance health and life sciences! Find out more: https://lnkd.in/gwrk3muC #EDDCsg #Panelist #APACSummit2024 #Innovation #HealthAndLifeSciences #Commercialisation 

On the 11th October 2024, we celebrated our third birthday! This year, we commemorated the occasion by inviting an ALL-STAR speakers' panel consisting of Dr. Ruifen Weng (CEO, DxD Hub - Diagnostics Development Hub) Dr. Pauline Erica Tay (Director, National Health Innovation Centre (NHIC)), Ms. Hsin-Ee Chia (Associate Director, Alliance Management, Experimental Drug Development Centre (EDDC)), and Dr. Dr. Sharon Loh (Senior Manager, Business Intelligence & Development, STCC, Consortium for Clinical Research and Innovation, Singapore (CRIS)). To add to the joyous occasion we witnessed the MOU signing between National Cancer Centre Singapore and DxD Hub - Diagnostics Development Hub, and marked exciting research collaborations with Illumina PacBio and KITKOJI. We would like to once again thank everyone for making time to mark this significant milestone with us, especially to our sponsors this year Illumina PacBio MGI Miltenyi Biotec QIAGEN Everlife Thermo Fisher Scientific NovogeneAIT Genomics Singleron Biotechnologies Agilent Technologies KITKOJI. The theme of the day is Bridging Research & Patient Care - and I am hopeful that as a community we can solve the problem of cancer, together! Tun Kiat Ko zhimei Li Jing Yi Lee Bavani Kannan Elizabeth Chun Yong Lee Lim Boon Yee (Bonnie) Vikneswari (Vicki) Rajasegaran Sara Haghani Hui Yi Tay Alun Guo

🔬 Advancing Cancer Diagnostics and Innovation at Cancer Discovery Hub Open House 2024 🔬 Thank you, Cancer Discovery Hub (CDH), for having us at the Cancer Discovery Hub Open House 2024, where our CEO Dr. Ruifen Weng, discussed the role of early diagnostics in preventive and precision care, and shared insights on challenges in development of an impactful diagnostics tool that is fit for purpose for the right patient at the right time! 🤝 A key highlight was the signing of a Memorandum of Understanding (MOU) between National Cancer Centre Singapore (NCCS) / CDH and DxD Hub - Diagnostics Development Hub (DxD Hub), formalising our ongoing collaboration to advance Asian-centric laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). This partnership will drive forward the development, commercialization, and adoption of innovative diagnostic solutions. We extend our appreciation to Prof. Jason Yongsheng Chan, MBBS-PhD (Director, CDH), for organizing an inspiring event and Ms. Hsin-Ee Chia (Associate Director, Alliance Management, EDDC), Dr. Pauline Erica Tay (Director, NHIC), and Dr. Sharon Loh (Senior Manager, Business Intelligence & Development, STCC) for sharing their expertise and aspirations for the community. Thank you NCCS for your leadership in precision medicine and to CDH for hosting such an impactful event. Together, we are hopeful towards these impactful collaborations to drive healthcare innovation and advancing cancer care for patients worldwide. 🌍 Experimental Drug Development Centre (EDDC) National Health Innovation Centre (NHIC) Consortium for Clinical Research and Innovation, Singapore (CRIS) #CancerResearch #DxDHub #PrecisionMedicine #HealthcareInnovation #Diagnostics #Collaboration #CancerDiscovery

At EDDC, we believe that mental health is as important as physical health.    This #WorldMentalHealthDay, we asked some of our Wellness Ambassadors to share their thoughts on this year's theme: "It is Time to Prioritise Mental Health in the Workplace". Swipe to see their inspiring quotes in prioritising mental well-being not just today, but everyday!   #EDDCsg #WorldMentalHealthDay2024 #MentalHealth #Itstimetoprioritizementalhealthintheworkplace #EmployeeWellbeing

We concluded our 3rd STDR Roadshow yesterday!   A big thank you to everyone who attended the session at Academia in the SingHealth and Duke-NUS Medical School campus. We’ve enjoyed the Q&A and hearing past STDR awardees share their experiences across NUS, NTU, and at Outram.   We hope that everyone who attended has found the sessions helpful and insightful. Let’s continue to work together to translate the great science in Singapore to technologies and products with patient impact! Jenefer Alam Changji Zou Ha T. #EDDCsg #STDR #TTC #DrugDiscovery #GrantCall #SingHealth #DukeNUS

A big thank you to everyone who joined us for the Singapore Therapeutics Development Review (STDR) roadshows at National University of Singapore and Nanyang Technological University Singapore! 🙌 It was fantastic to connect with all of you who participated. We hope the sessions were insightful in discovering more about STDR's programmes, mentorship, training and grant opportunities.    Special thanks to Dr Dennis Kappei, Prof Nicholas Gascoigne, and Prof Pablo Bifani for sharing your experiences with us.   Next Monday will be our final stop at SingHealth Duke-NUS Medical School Outram Campus! We look forward to hearing from the STDR, EDDC and SMART presenters, as well as sharings from former grant awardees Dr Cheryl Lee and Dr Alice Cheung. #EDDCsg #STDR #TTC #DrugDiscovery #GrantCall Christophe Bodenreider Howard Califano Hsin-Ee Chia Ha T. Siti Munirah Abdul Karim

📢 Last Call 📢 The STDR On-Campus Roadshow commences tomorrow! Dr Howard Califano joins us at NUS and Outram Campus to speak on Attributes on Successful Applications with Dr Christophe Bodenreider. We can't wait to see you there! Sign up links are below: National University of Singapore: https://lnkd.in/gu2E4-c5 Nanyang Technological University Singapore: https://lnkd.in/gbb3y-4T SingHealth Duke-NUS Medical School Outram Campus: https://lnkd.in/g8PmgrPr #EDDCsg #STDR #TTC #DrugDiscovery #GrantCall